Disclosed herein are nucleoside compounds and derivatives thereof, pharmaceutical compositions containing same, and their methods of synthesis. The compounds are useful in treating orthomyxovirus infections, such as influenza infections.

##STR00001##

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

A method for preparing an intermediate by a reduced glutathione-indicated amino acid Maillard reaction is provided. The method includes a two-stage reaction at an increased temperature. A reduced glutathione is added after different times of a low-temperature reaction, and a subsequent Maillard reaction is effectively inhibited on a basis wherein a substance is interacted with an intermediate degradation product to reduce a formation of colored substances. Comparing with a browning of Maillard products after a high-temperature stage, a reaction time with a best color inhibition effect is found to be the optimal preparation condition of the intermediate, and the intermediate is prepared in an aqueous medium at a low temperature under this optimal preparation condition. The method uses the water soluble reduced glutathione as a tracer to improve a tracing accuracy comparing to cysteine.

A method for preparing an intermediate by a reduced glutathione-indicated amino acid Maillard reaction is provided. The method includes a two-stage reaction at an increased temperature. A reduced glutathione is added after different times of a low-temperature reaction, and a subsequent Maillard reaction is effectively inhibited on a basis wherein a substance is interacted with an intermediate degradation product to reduce a formation of colored substances. Comparing with a browning of Maillard products after a high-temperature stage, a reaction time with a best color inhibition effect is found to be the optimal preparation condition of the intermediate, and the intermediate is prepared in an aqueous medium at a low temperature under this optimal preparation condition. The method uses the water soluble reduced glutathione as a tracer to improve a tracing accuracy comparing to cysteine.

Disclosed herein are novel catalysts for producing remdesivir in one-pot manner, in which a diastereomerically enriched form of an intermediate, which following acidic hydrolysis would give rise to the desired remdesivir, was produced with the aid of the disclosed novel catalysts. Also disclosed herein is an improved process for the preparation of remdesivir without the need to separate one of the enantiomers while minimizing the formation of undesired isomers, thus offers economic advantages for operation on a commercial scale.

Disclosed herein are novel catalysts for producing remdesivir in one-pot manner, in which a diastereomerically enriched form of an intermediate, which following acidic hydrolysis would give rise to the desired remdesivir, was produced with the aid of the disclosed novel catalysts. Also disclosed herein is an improved process for the preparation of remdesivir without the need to separate one of the enantiomers while minimizing the formation of undesired isomers, thus offers economic advantages for operation on a commercial scale.

Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or the isomers (optical, geometric, tautomers) thereof and/or the salts thereof: (I) ##STR00001##